Biocon's Biosimilar Blues episode artwork

EPISODE · Mar 3, 2022 · 24 MIN

Biocon's Biosimilar Blues

from The Morning Brief · host The Economic Times

Biocon’s recent acquisition of its partner Viatris Inc.'s biosimilar business has shocked the investors as the company’s shares fell nearly 12% on the bourses. Host Dia Rekhi along with Biocon Biologics’ Deputy CEO Shreehas Tambe, ET’s Kiran Somvanshi, and ET Prime’s Vikas Dandekar break down the deal means for the company and the investors and whether the $3.3-billion bet is worth the risk? Credits: ET NowSee omnystudio.com/listener for privacy information.

NOW PLAYING

Biocon's Biosimilar Blues

0:00 24:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Morning Brief?

This episode is 24 minutes long.

When was this The Morning Brief episode published?

This episode was published on March 3, 2022.

What is this episode about?

Biocon’s recent acquisition of its partner Viatris Inc.'s biosimilar business has shocked the investors as the company’s shares fell nearly 12% on the bourses. Host Dia Rekhi along with Biocon Biologics’ Deputy CEO Shreehas Tambe, ET’s Kiran...

Can I download this The Morning Brief episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!